TD Cowen analyst Steve Scala maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of $45.00. The ...

It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...